{'fraction_non_alphanumeric': 0.013265306122448979, 'fraction_numerical': 0.0010204081632653062, 'mean_word_length': 5.86013986013986, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reply to Comments on “Subtherapeutic Linezolid Concentrations in a Patient With Morbid Obesity and Methicillin-Resistant Staphylococcus aureus Pneumonia: Case Report and Review of the Literature”

TO THE EDITOR: We thank the authors for their comments regarding our report of subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia. We acknowledge that data were omitted regarding specific details of medication administration via enteral feeding tube. On additional chart review, we discovered that while initial linezolid doses were administered as suspension via enteral feeding tube, doses around the time of linezolid drug level acquisition were actually tablets administered via the oral route. These changes occurred subsequent to liberation from mechanical ventilation and had been in place for approximately 5 days prior to drug level acquisition. The authors apologize for this crucial omission.